Search results
Showing 1 result for pegloticase
Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)
The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.